Do analysts rate SVA or AVBP?

ArriVent BioPharma has a consensus target price of $44.86, indicating a potential upside of 54.04%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ArriVent BioPharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has preferable earnings and valuation, SVA or AVBP?

Sinovac Biotech has higher revenue and earnings than ArriVent BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A

Is SVA or AVBP more profitable?

Sinovac Biotech's return on equity of 0.00% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A ArriVent BioPharma N/A -50.26% -46.66%

Which has higher earnings and valuation, ORIC or SVA?

Sinovac Biotech has higher revenue and earnings than Oric Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is ORIC or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Sinovac Biotech N/A N/A N/A

Do analysts recommend CGEM or SVA?

Cullinan Therapeutics currently has a consensus target price of $32.86, suggesting a potential upside of 51.56%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, CGEM or SVA?

Sinovac Biotech has higher revenue and earnings than Cullinan Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is CGEM or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Sinovac Biotech N/A N/A N/A

Do analysts recommend SVA or VOR?

Vor Biopharma has a consensus price target of $43.38, indicating a potential upside of 85.68%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Which has better earnings & valuation, SVA or VOR?

Vor Biopharma has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Vor Biopharma N/A N/A N/A N/A N/A

Is SVA or VOR more profitable?

Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Vor Biopharma N/A N/A N/A

Do analysts rate SVA or OMER?

Omeros has a consensus target price of $38.00, suggesting a potential upside of 97.20%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Omeros 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, SVA or OMER?

Omeros has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Omeros N/A N/A -$3.35M $1.28 15.05

Is SVA or OMER more profitable?

Sinovac Biotech's return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Omeros N/A -164.92% 69.41%

Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 08/21/2026

Compare

SVA vs. AVBP, ORIC, CGEM, VOR, and OMER

Should you buy Sinovac Biotech stock or one of its competitors? Sinovac Biotech's main competitors and comparable companies include ArriVent BioPharma (AVBP), Oric Pharmaceuticals (ORIC), Cullinan Therapeutics (CGEM), Vor Biopharma (VOR), and Omeros (OMER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sinovac Biotech compare to ArriVent BioPharma?

Sinovac Biotech (NASDAQ:SVA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Sinovac Biotech's return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
ArriVent BioPharma	N/A	-50.26%	-46.66%

In the previous week, ArriVent BioPharma had 16 more articles in the media than Sinovac Biotech. MarketBeat recorded 16 mentions for ArriVent BioPharma and 0 mentions for Sinovac Biotech. ArriVent BioPharma's average media sentiment score of 0.54 beat Sinovac Biotech's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
ArriVent BioPharma	Positive

Sinovac Biotech has higher revenue and earnings than ArriVent BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

ArriVent BioPharma has a consensus target price of $44.86, indicating a potential upside of 54.04%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

ArriVent BioPharma beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Oric Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 0 mentions for Sinovac Biotech. Oric Pharmaceuticals' average media sentiment score of 1.14 beat Sinovac Biotech's score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Positive
Sinovac Biotech	Neutral

Sinovac Biotech's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Sinovac Biotech	N/A	N/A	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sinovac Biotech has higher revenue and earnings than Oric Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Oric Pharmaceuticals presently has a consensus target price of $19.45, suggesting a potential upside of 37.00%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oric Pharmaceuticals is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oric Pharmaceuticals beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Sinovac Biotech has higher revenue and earnings than Cullinan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Cullinan Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Cullinan Therapeutics and 0 mentions for Sinovac Biotech. Cullinan Therapeutics' average media sentiment score of 0.39 beat Sinovac Biotech's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Sinovac Biotech	Neutral

Sinovac Biotech's return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Sinovac Biotech	N/A	N/A	N/A

Cullinan Therapeutics currently has a consensus target price of $32.86, suggesting a potential upside of 51.56%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cullinan Therapeutics and Sinovac Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Vor Biopharma?

Sinovac Biotech (NASDAQ:SVA) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Vor Biopharma has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Sinovac Biotech's average media sentiment score of 0.00 equaled Vor Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Vor Biopharma	Neutral

Vor Biopharma has a consensus price target of $43.38, indicating a potential upside of 85.68%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

97.3% of Vor Biopharma shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Vor Biopharma	N/A	N/A	N/A

Summary

Vor Biopharma beats Sinovac Biotech on 6 of the 8 factors compared between the two stocks.

How does Sinovac Biotech compare to Omeros?

Sinovac Biotech (NASDAQ:SVA) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

48.8% of Omeros shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omeros has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	15.05

Omeros has a consensus target price of $38.00, suggesting a potential upside of 97.20%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Omeros had 9 more articles in the media than Sinovac Biotech. MarketBeat recorded 9 mentions for Omeros and 0 mentions for Sinovac Biotech. Omeros' average media sentiment score of 0.41 beat Sinovac Biotech's score of 0.00 indicating that Omeros is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Omeros	Neutral

Sinovac Biotech has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Omeros	N/A	-164.92%	69.41%

Summary

Omeros beats Sinovac Biotech on 10 of the 13 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$644.67M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	N/A	11.68	272.90	24.25
Price / Sales	1.67	1,350.74	632.64	97.63
Price / Cash	11.89	44.94	29.03	36.90
Price / Book	0.07	17.38	11.25	6.42
Net Income	-$59.68M	-$22.72M	$3.47B	$348.89M
7 Day Performance	N/A	3.03%	2.33%	0.57%
1 Month Performance	N/A	9.82%	7.72%	4.90%
1 Year Performance	N/A	55.05%	25.22%	17.06%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	N/A	$6.47 flat	N/A	N/A	$644.67M	$386.01M	N/A	3,008	High Trading Volume
AVBP ArriVent BioPharma	2.2473 of 5 stars	$29.47 +1.0%	$44.86 +52.2%	+44.8%	$1.45B	N/A	N/A	40
ORIC Oric Pharmaceuticals	2.4826 of 5 stars	$13.91 +0.2%	$19.45 +39.9%	+45.8%	$1.44B	N/A	N/A	80
CGEM Cullinan Therapeutics	2.5068 of 5 stars	$21.73 +1.6%	$32.86 +51.2%	+164.7%	$1.40B	N/A	N/A	30
VOR Vor Biopharma	2.0292 of 5 stars	$23.60 +2.3%	$43.38 +83.8%	-46.2%	$1.40B	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. AVBP, ORIC, CGEM, VOR, and OMER

How does Sinovac Biotech compare to ArriVent BioPharma?

Summary

How does Sinovac Biotech compare to Oric Pharmaceuticals?

Summary

How does Sinovac Biotech compare to Cullinan Therapeutics?

Summary

How does Sinovac Biotech compare to Vor Biopharma?

Summary

How does Sinovac Biotech compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. AVBP, ORIC, CGEM, VOR, and OMER

How does Sinovac Biotech compare to ArriVent BioPharma?

Is SVA or AVBP more profitable?

Does the media prefer SVA or AVBP?

Which has preferable earnings and valuation, SVA or AVBP?

Do insiders and institutionals believe in SVA or AVBP?

Which has more volatility & risk, SVA or AVBP?

Do analysts rate SVA or AVBP?

Summary

How does Sinovac Biotech compare to Oric Pharmaceuticals?

Which has more volatility and risk, ORIC or SVA?

Does the media favor ORIC or SVA?

Is ORIC or SVA more profitable?

Do institutionals and insiders hold more shares of ORIC or SVA?

Which has higher earnings and valuation, ORIC or SVA?

Do analysts prefer ORIC or SVA?

Summary

How does Sinovac Biotech compare to Cullinan Therapeutics?

Which has better valuation and earnings, CGEM or SVA?

Which has more volatility & risk, CGEM or SVA?

Do insiders and institutionals hold more shares of CGEM or SVA?

Does the media favor CGEM or SVA?

Is CGEM or SVA more profitable?

Do analysts recommend CGEM or SVA?

Summary

How does Sinovac Biotech compare to Vor Biopharma?

Which has more volatility and risk, SVA or VOR?

Which has better earnings & valuation, SVA or VOR?

Does the media prefer SVA or VOR?

Do analysts recommend SVA or VOR?

Do insiders & institutionals believe in SVA or VOR?

Is SVA or VOR more profitable?

Summary

How does Sinovac Biotech compare to Omeros?

Do insiders and institutionals hold more shares of SVA or OMER?

Which has stronger earnings and valuation, SVA or OMER?

Do analysts rate SVA or OMER?

Does the media favor SVA or OMER?

Which has more volatility and risk, SVA or OMER?

Is SVA or OMER more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools